Abdul-Aziz MH, Hammond NE, Brett SJ, Cotta MO, De Waele JJ, Devaux A, et al. Prolonged vs Intermittent Infusions of beta-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis. JAMA 2024. https://www.ncbi.nlm.nih.gov/pubmed/38864162
Chewapreecha C, Holden MT, Vehkala M, Valimaki N, Yang Z, Harris SR, et al. Global and regional dissemination and evolution of Burkholderia pseudomallei. Nat Microbiol 2017;2:16263. https://www.ncbi.nlm.nih.gov/pubmed/28112723
Crowe A, McMahon N, Currie BJ, Baird RW. Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia. Int J Antimicrob Agents 2014;44(2):160–2. https://www.ncbi.nlm.nih.gov/pubmed/24924662
Currie BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med 2015;36(1):111–25. https://www.ncbi.nlm.nih.gov/pubmed/25643275
Dance DA, Davong V, Soeng S, Phetsouvanh R, Newton PN, Turner P. Trimethoprim/sulfamethoxazole resistance in Burkholderia pseudomallei. Int J Antimicrob Agents 2014;44(4):368–9. https://www.ncbi.nlm.nih.gov/pubmed/25245211
Dulhunty JM, Brett SJ, De Waele JJ, Rajbhandari
D, Billot L, Cotta MO, et al. Continuous vs Intermittent beta-Lactam Antibiotic
Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized
Clinical Trial. JAMA 2024. https://www.ncbi.nlm.nih.gov/pubmed/38864155
Geake JB, Reid DW, Currie BJ, Bell SC, Melioid CFI, Bright-Thomas R, et al. An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis. BMC Pulm Med 2015;15:116. https://www.ncbi.nlm.nih.gov/pubmed/26453341
Limmathurotsakul D, Golding N, Dance DA, Messina JP, Pigott DM, Moyes CL, et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol 2016;1:15008. https://www.ncbi.nlm.nih.gov/pubmed/27571754
Pitman MC, Luck T, Marshall CS, Anstey NM, Ward L, Currie BJ. Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm. PLoS Negl Trop Dis 2015;9(3):e0003586. https://www.ncbi.nlm.nih.gov/pubmed/25811783
Saiprom N, Amornchai P, Wuthiekanun V, Day NP, Limmathurotsakul D, Peacock SJ, et al. Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei from Thailand. Int J Antimicrob Agents 2015;45(5):557–559. https://www.ncbi.nlm.nih.gov/pubmed/25758020
Sarovich DS, Garin B, De Smet B, Kaestli M, Mayo M, Vandamme P, et al. Phylogenomic analysis reveals an Asian origin for African Burkholderia pseudomallei and further supports melioidosis endemicity in Africa. mSphere 2016;1(2). https://www.ncbi.nlm.nih.gov/pubmed/27303718
